Citations

Showing 10 of 108083 citations.

Skeletal muscle 99mTechnetium‐pyrophosphate scan: More questions than answers
Pinto, Marcus Vinícius , Liewluck, Teerin , Pinto, Marcus V , Liewluck, T

Mayo Clinic

Muscle & Nerve | November 16, 2022 | Volume: 67 | Issue: 2 | Pages: 98-100

10.1002/mus.27754 | PMID 36382940 Get It

See article on pages 111‐116 in this issue.
Neurotization during Breast Reconstruction
Morris, Bryn E., Spronsen, Nicole R. Van, Shrout, Max A., Teven, Chad M. , Rebecca, Alanna M. , Van Spronsen, Nicole R, Spronsen, Nicole Van

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | November 16, 2022 | Volume: 10 | Issue: 11 | Pages: e4591

10.1097/gox.0000000000004591 | PMID 36405045 Get It

Faculty Opinions recommendation of Primary cilia on muscle stem cells are critical to maintain regenerative capacity and are lost during aging.
LeBrasseur, Nathan K. , Zhang, Xu

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 16, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.741866620.793596504 Get It

Letter to the editor regarding ‘Anatomical study of the medial branches of the lumbar dorsal rami: implications for image-guided intervention’
Bryant, Douglas , Dovgan, Jakob T. , Hunt, Christine , Beckworth, William Jeremy , Rivers, W. Evan , Dovgan, Jakob Thomas , Hunt, Christine , Waring, Patrick H

Mayo Clinic

Regional Anesthesia & Pain Medicine | November 16, 2022 | Volume: 48 | Issue: 2 | Pages: 94-94

10.1136/rapm-2022-104119 | PMID 36384876 Get It

Antibodies as drugs—a Keystone Symposia report
Cable, Jennifer, Wiltshire, Timothy D. , Mousa, Jarrod J. , Humphreys, David P., Breij, Esther C.W. , Bruhns, Pierre , Broketa, Matteo , Furuya, Genta , Hauser, Blake M. , Mahévas, Matthieu , Kwong, Peter D. , Davis, Jonathan H. , Brewis, Neil , Keyt, Bruce A. , Fennemann, Felix L. , Dussupt, Vincent , Rawi, Reda , Wolters, Rachael M. , Geuijen, Cecile, Sleeman, Matthew A. , Pengo, Niccolò , Donnellan, Francesca R. , Saphire, Erica Ollmann , Hayday, Adrian , Carfı́, Andrea , Cantaert, Tineke , Tripathi, Prabhanshu , Sivasubramanian, Arvind, Kim, Philip M. , Richardson, Eve , Leventhal, Daniel

Mayo Clinic

Annals of the New York Academy of Sciences | November 16, 2022 | Volume: 1519 | Issue: 1 | Pages: 153-166

10.1111/nyas.14915 | PMID 36382536 Get It

AbstractTherapeutic antibodies have broad indications across diverse disease states, such as oncology, autoimmune diseases, and infectious diseases. New research continues to identify antibodies with therapeutic potential as well as methods to improve upon endogenous antibodies and to design antibodies de novo. On April 27–30, 2022, experts in antibody research across academia and industry met for the Keystone symposium “Antibodies as Drugs” to present the state‐of‐the‐art in antibody therapeutics, repertoires and deep learning, bispecific antibodies, and engineering.
Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
Su, Christopher , Nizialek, Emily , Berchuck, Jacob E. , Vlachostergios, Panagiotis J. , Ashkar, Ryan, Sokolova, Alexandra , Aggarwal, Rahul , McKay, Rana R. , Nafissi, Nellie , Bryce, Alan H. , Taplin, Mary‐Ellen , Cieślik, Marcin , Alva, Ajjai , Antonarakis, Emmanuel S. , Antonarakis, Emmanuel S. , Su, Christopher , Nafissi, Nellie N , Bryce, Alan H , Sartor, A Oliver , Sayegh, Nicolas , Cheng, Heather H , Antonarakis, Emmanuel S , Vlachostergios, Panagiotis J , Antonarakis, Emmanuel S , Barata, Pedro C. , Agarwal, Neeraj , McClure, Heather M. , Sartor, Oliver , Cheng, Heather H. , Adra, Nabil , Sternberg, Cora N

Mayo Clinic

The Prostate | November 16, 2022 | Volume: 83 | Issue: 3 | Pages: 227-236

10.1002/pros.24454 | PMID 36382533 Get It

AbstractBackgroundPARP (poly(ADP‐ribose) polymerase) inhibitors (PARPi) are now standard of care in metastatic castrate‐resistant prostate cancer (mCRPC) patients with select mutations in DNA damage repair (DDR) pathways, but patients with ATM‐ and BRCA2 mutations may respond differently to PARPi. We hypothesized that differences may also exist in response to taxanes, which may inform treatment sequencing decisions.MethodsmCRPC patients (N = 158) with deleterious ATM or BRCA2 mutations who received taxanes, PARPi, or both were retrospectively identified from 11 US academic centers. Demographic, treatment, and survival data were collected. Kaplan−Meier analyses were performed and Cox hazard ratios (HR) were calculated for progression‐free survival (PFS) as well as overall survival (OS), from time of first taxane or PARPi therapy.ResultsFifty‐eight patients with ATM mutations and 100 with BRCA2 mutations were identified. Fourty‐four (76%) patients with ATM mutations received taxane only or taxane before PARPi, while 14 (24%) received PARPi only or PARPi before taxane. Patients with ATM mutations had longer PFS when taxane was given first versus PARPi given first (HR: 0.74 [95% confidence interval [CI]: 0.37−1.50]; p = 0.40). Similarly, OS was longer in patients with ATM mutations who received taxane first (HR: 0.56 [CI: 0.20−1.54]; p = 0.26). Among patients with BRCA2 mutations, 51 (51%) received taxane first and 49 (49%) received PARPi first. In contrast, patients with BRCA2 mutations had longer PFS when PARPi was given first versus taxane given first (HR: 0.85 [CI: 0.54−1.35]; p = 0.49). Similarly, OS was longer in patients with BRCA2 mutations who received PARPi first (HR: 0.75 [CI: 0.41−1.37]; p = 0.35).ConclusionsOur retrospective data suggest differential response between ATM and BRCA2 mutated prostate cancers in terms of response to PARPi and to taxane chemotherapy. When considering the sequence of PARPi versus taxane chemotherapy for mCRPC with DDR mutations, ATM, and BRCA2 mutation status may be helpful in guiding choice of initial therapy.
Factors Impacting the Yield of Image-Guided Biopsy in Native Vertebral Osteomyelitis: A 10-Year Retrospective Study
Maamari, Julian , Tai, Don Bambino Geno , Ross, Courtney, Lahr, Brian D. , Suh, Gina A. , Berbari, Elie F. , Maamari, Julian , Diehn, Felix E. , Suh, Gina A , Berbari, Elie F , Tai, Don Bambino Geno , Tande, Aaron J.

Mayo Clinic

Open Forum Infectious Diseases | November 16, 2022 | Volume: 9 | Issue: 12 | Pages: No page available

10.1093/ofid/ofac616 | PMID 36570966 Get It

Abstract Background Image-guided biopsies in patients with suspected native vertebral osteomyelitis (NVO) are recommended to establish the microbiological diagnosis and guide antibiotic therapy. Despite recent advances, the microbiological yield of this procedure remains between 48% and 52%. A better understanding of factors associated with this low yield may lead to improved microbiological diagnosis. Methods We retrospectively identified patients with suspected NVO undergoing image-guided biopsies from January 2011 to June 2021 at our institution. Two hundred nine patients undergoing 248 percutaneous biopsies were included. Demographic data, biopsy and microbiologic techniques, clinical characteristics, and antibiotic use were collected. Multivariable logistic regression analysis was conducted to determine factors associated with microbiological yield. Results A total of 110 of 209 (52.6%) initial image-guided biopsies revealed positive microbiological results. This number increased to 121 of 209 (57.9%) when repeat image-guided biopsies were included. In multivariable analysis, aspiration of fluid was associated with a 3-fold increased odds of yielding a positive result (odds ratio [OR], 3.13; 95% confidence interval [CI], 1.39–7.04; P = .006), whereas prior antibiotic use was associated with a 3-fold decreased yield (OR, 0.32; 95% CI, .16–.65; P = .002). A univariate subgroup analysis revealed a significant association between the length of the antibiotic-free period and microbiological yield, with the lowest rates of pathogen detection at 0–3 days and higher rates as duration increased (P = .017). Conclusions Prior antibiotic use in patients with suspected NVO was associated with a decrease in the microbiological yield of image-guided biopsies. An antibiotic-free period of at least 4 days is suggested to maximize yield. Successful fluid aspiration during the procedure also increases microbiological yield.
The Arterial Pattern of the Upper Nasal Septum (S‐Point) and Potential Role in Severe Epistaxis
Rezende, Natalia , Leonel, Luciano, Kosugi, Eduardo Macoto , Pinheiro‐Neto, Carlos , Peris‐Celda, Maria , Rezende, Natália Cerqueira , Leonel, Luciano César Pereira Campos , Pinheiro-Neto, Carlos D

Mayo Clinic

The Laryngoscope | November 16, 2022 | Volume: 133 | Issue: 9 | Pages: 2075-2080

10.1002/lary.30487 | PMID 36382868 Get It

Objectives The previously described S‐point, corresponds to the medial projection of the middle turbinate axilla in the superior nasal septum and has been identified as a common source of severe epistaxis. The objective is to define the anatomical patterns of vascularization of the S‐point area that could explain its clinical relevance. Methods Thirty‐three nasal septums of latex‐injected formalin‐embalmed and fresh human cadaveric heads were dissected to analyze the arterial arrangement of the S‐point area. Measurements and patterns of vascularization were described. Results The S‐point area, was consistently surrounded by a single or multiple arterial anastomotic arches consistently formed superiorly by the anterior ethmoidal and posterior ethmoidal artery branches, and inferiorly by the posterior septal artery. The caliber of the arterial arches was typically larger than the caliber of the arterial branches supplying them. A single arch was present in 36.3% of septums, and multiple arches in 63.6%. The mean distance from the S‐point to the anterior limit of the arch was 9 mm, to the posterior arch when the present was 3 mm, to the superior limit 6 mm, to the inferior limit 6 mm, and to the nasal roof was 10 mm. Conclusion This study demonstrates the dense arterial configuration of the S point area, which is characterized by a single or multiple vascular arches of greater caliber than the branches of origin. This finding could explain why the S‐point area is a frequent source of epistaxis, and guide its surgical cauterization when an obvious vascular ectasia is not visualized. Level of Evidence N/A Laryngoscope , 133:2075–2080, 2023
Development of a Clinical Prediction Model for Diabetes in Chronic Pancreatitis: The PREDICT3c Study
Hart, Phil A. , Li, Liang , Yang, Yunlong, Chang, Eleanor, Bellin, Melena D. , Fisher, William E., Fogel, Evan L. , Forsmark, Christopher E., Park, Walter G. , Vege, Santhi Swaroop , Andersen, Dana K. , Conwell, Darwin L. , Yadav, Dhiraj , Goodarzi, Mark O. , Bellin, Melena D , Yadav, Dhiraj , Goodarzi, Mark O , Jeon, Christie Y. , Van Den Eeden, Stephen K , Serrano, José , Whitcomb, David C. , Conwell, Darwin L.

Mayo Clinic

Diabetes Care | November 16, 2022 | Volume: 46 | Issue: 1 | Pages: 46-55

10.2337/dc22-1414 | PMID 36382801 Get It

OBJECTIVE Diabetes that arises from chronic pancreatitis (CP) is associated with increased morbidity and mortality. Methods to predict which patients with CP are at greatest risk for diabetes are urgently needed. We aimed to examine independent risk factors for diabetes in a large cohort of patients with CP. RESEARCH DESIGN AND METHODS This cross-sectional study comprised 645 individuals with CP enrolled in the PROCEED study, of whom 276 had diabetes. We conducted univariable and multivariable regression analyses of potential risk factors for diabetes. Model performance was assessed by area under the receiver operating characteristic curve (AUROC) analysis, and accuracy was evaluated by cross validation. Exploratory analyses were stratified according to the timing of development of diabetes relative to the diagnosis of pancreatitis. RESULTS Independent correlates of diabetes in CP included risk factors for type 2 diabetes (older age, overweight/obese status, male sex, non-White race, tobacco use) as well as pancreatic disease–related factors (history of acute pancreatitis complications, nonalcoholic etiology of CP, exocrine pancreatic dysfunction, pancreatic calcification, pancreatic atrophy) (AUROC 0.745). Type 2 diabetes risk factors were predominant for diabetes occurring before pancreatitis, and pancreatic disease–related factors were predominant for diabetes occurring after pancreatitis. CONCLUSIONS Multiple factors are associated with diabetes in CP, including canonical risk factors for type 2 diabetes and features associated with pancreatitis severity. This study lays the groundwork for the future development of models integrating clinical and nonclinical data to identify patients with CP at risk for diabetes and identifies modifiable risk factors (obesity, smoking) on which to focus for diabetes prevention.
Fungal infection and colonization in lung transplant recipients with chronic lung allograft dysfunction
Pennington, Kelly M. , Martinu, Tereza , Johnson, Bradley K. , Johnson, Bradley, Aversa, Meghan M. , Husain, Shahid

Mayo Clinic

Transplant Infectious Disease | November 16, 2022 | Volume: 24 | Issue: 6 | Pages: No page available

10.1111/tid.13986 | PMID 36380578 Get It

AbstractBackgroundThe incidence and impact of de novo fungal airway colonization and infection in lung transplant recipients (LTRs) with known chronic lung allograft dysfunction (CLAD) has not been established. We aimed to determine the 1‐year cumulative incidence and risk factors of de novo fungal colonization or infection in LTRs with CLAD and assess the impact of colonization or infection on post‐CLAD survival.MethodsProspectively collected Toronto Lung Transplant Program database and chart review were used for double‐LTRs who were diagnosed with CLAD from January 1, 2016 to January 1, 2020 and who were free of airway fungi within 1 year prior to CLAD onset. International Society for Heart and Lung Transplantation definitions were used to define clinical syndromes. Cox‐Proportional Hazards Models were used for risk‐factor analysis. Survival analysis could not be completed secondary to low number of fungal events; therefore, descriptive statistics were employed for survival outcomes.ResultsWe found 186 LTRs diagnosed with CLAD meeting our inclusion criteria. The 1‐year cumulative incidence for any fungal event was 11.8% (7.0% for infection and 4.8% for colonization). Aspergillus fumigatus was a causative pathogen in eight of 13 (61.5%) patients with infection and six of nine (66.7%) patients with colonization. No patients with fungal colonization post‐CLAD developed fungal infection. Peri‐CLAD diagnosis (3 months prior or 1 month after) methylprednisolone bolus (hazards ratio: 8.84, p = .001) increased the risk of fungal events. Most patients diagnosed with fungal infections (53.8%) died within 1‐year of CLAD onset.ConclusionDe novo IFIs and fungal colonization following CLAD onset were not common. Fungal colonization did not lead to fungal infection. Methylprednisolone bolus was a significant risk factors for post‐CLAD fungal events. image